Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.
about
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerConcordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatinC-Jun N-terminal kinase signalling pathway in response to cisplatinSynthetic and natural antioxidants attenuate cisplatin-induced vomitingAdverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerGynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeProteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells.Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapyAn orthotopic model of platinum-sensitive high grade serous fallopian tube carcinomaSuppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagyThymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancerPharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsHalf-sandwich RuCl2(η(6)-p-cymene) core complexes containing sulfur donor aroylthiourea ligands: DNA and protein binding, DNA cleavage and cytotoxic studies.Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling PathwaysAdvantages of the avian model for human ovarian cancer'BRCAness' and its implications for platinum action in gynecologic cancer.Effects of solvents on in vitro potencies of platinum compoundsIs renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinomaTargeting drug transport mechanisms for improving platinum-based cancer chemotherapy.Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancerRetained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer.Renal Medulla is More Sensitive to Cisplatin than Cortex Revealed by Untargeted Mass Spectrometry-Based Metabolomics in RatsOvercoming platinum drug resistance with copper-lowering agents.
P2860
Q24187899-F7E57486-0E8D-48A7-8103-45AB4AE684D3Q24234893-3D0A3E25-5F24-4EF7-A0E9-58859DFEA507Q24306623-A07FA512-3637-45C4-8AE8-F5344DBDF4B0Q26745463-5AD29A95-B12D-4051-B39C-7347EB696BF0Q30834914-EE70831F-645B-4ECB-97BF-B1848BE773A3Q33397057-F1BC4E37-8BEF-4569-A4FE-E71C1A55A132Q33509648-BB101C54-A18E-434C-A6DE-124B7C5D3DFEQ33572313-DC1A0AD2-BF54-45BD-8B9A-7842D0005253Q33578400-06EA625F-4561-4A4D-B91E-75809300A0EFQ33659166-53E98FDF-FAC4-4658-97C4-E3857EC28F11Q33837836-8F7817B0-E420-4DA5-A294-04A995AD45C8Q33858199-BCBBB8A8-781D-4DF8-A3B5-FE082A343E84Q34159386-8FDBEC62-F6E8-48AA-AC31-3D8BF9ABD45EQ34381630-23366752-51FD-465D-AB41-82177A4A8904Q34540820-E335F0BB-8F4C-40B8-AC6E-68BAE37764F6Q35141276-84447F33-14A4-4928-A078-0F1CA4B2C9A0Q35702786-8D727573-419A-47DF-A976-18F65863B02DQ35772988-63593D2F-AD2D-4C59-AD4B-58A7454B13AEQ35852880-5EE12133-D4D6-4A3E-9CAC-DA235C8060DDQ35896471-E9A74BB8-A0EC-4471-9CB5-3DC8DCCD3B39Q35977483-3B00049A-64F5-4DF7-9347-B241930F0504Q36082052-F7B13374-3A9A-41E9-8514-F2DF6D21C7E4Q36267621-DDE386C1-B6CC-473A-8382-5A0D43CB5D91Q36296657-B754229E-8DA7-4194-A681-489ABB4402A2Q36334681-F81DF3C2-E2CF-4B38-8574-0179CC4E2A22Q36380704-C29CEBEE-6B2D-4D62-8850-AB75028CFAD1Q36429953-3C466BC8-3179-443A-AB05-D7B384333DE0Q36483166-343441CD-3147-46A2-B007-F11C7B17037BQ36521908-E0E8BEFD-4149-4556-8558-A07EAECB79B4Q36544635-B0F366D1-EEEF-4376-99CF-A9B917E12A2EQ36841450-5A37E1CD-4E37-47B8-962C-8C01D881E54BQ36853421-3AE939C6-F6AB-4F98-864D-E8C7647EAB2FQ36920272-65C67629-6DFD-4D8B-B728-86A50A2093B1Q37015742-A761815B-9CF7-423C-AF3F-ECE463174A7EQ37295775-CF320383-1342-4274-BF33-35D68EC0126EQ37328373-7F3A6A1E-7396-4AE6-9139-73F76219180AQ37470105-56E0E854-8CF2-413B-ADA3-F992BB1C2A1FQ37684614-47EED5EB-E521-4B7C-A955-AB699BB01BC9Q37704672-DD1C4EB6-B326-4BB4-B182-C67335EAC821Q37727299-000C6A4A-7FB4-4394-A4F6-AF8D27D87233
P2860
Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@en
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@nl
type
label
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@en
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@nl
prefLabel
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@en
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@nl
P1433
P1476
Platinum compounds 30 years af ...... e treatment of ovarian cancer.
@en
P304
P356
10.1016/J.YGYNO.2008.09.034
P407
P577
2008-10-31T00:00:00Z